A MET Targeting Antibody–Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer
- 15 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (7), 2100-2110
- https://doi.org/10.1158/1078-0432.ccr-20-3210
Abstract
Purpose: Pancreatic cancer is an aggressive disease associated with a poor 5-year overall survival. Most patients are ineligible for surgery due to late diagnosis and are treated primarily with chemotherapy with very limited success. Pancreatic cancer is relatively insensitive to chemotherapy due to multiple factors including reduced bioavailability of drugs to tumor cells. One strategy to improve drug efficacy with reduced toxicity is the development of antibody-drug conjugates which have now been used successfully to treat both solid and liquid tumors. Here we evaluate the efficacy of TR1801-ADC, a newly developed ADC composed of a MET antibody conjugated to the highly potent pyrrolobenzodiazepine toxin-linker Tesirine. Experimental Design: We first evaluated MET expression and subcellular localization in pancreatic cancer cell lines, human tumors and patient derived xenografts. We then tested TR1801-ADC efficacy in vitro in pancreatic cancer cell lines. Preclinical evaluation of TR1801-ADC efficacy was conducted on patient derived xenografts selected based on their MET expression level. Results: We show that MET is highly expressed and located at the plasma membrane of pancreatic cancer cells. We found that TR1801-ADC induces a specific cytotoxicity in pancreatic cancer cell lines and a profound tumor growth inhibition, even in a gemcitabine resistant tumor. We also noted synergism between TR1801-ADC and gemcitabine in vitro and an improved response to the combination in vivo. Conclusions: Together these results suggest the promise of agents such as TR1801-ADC as a novel approach to the treatment of pancreatic cancer.Other Versions
Funding Information
- Tanabe Research Laboratories U.S.A., Inc.
- NIH (CA155620)
This publication has 32 references indexed in Scilit:
- Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumorJournal of Translational Medicine, 2014
- Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic CancerCurrent Pharmaceutical Design, 2013
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancerGut, 2012
- The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor traffickingOncogene, 2011
- Pancreatic CancerThe New England Journal of Medicine, 2010
- Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient miceNature Protocols, 2009
- Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling OutcomesMolecular Cell, 2009
- Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor CellsAnnals of Surgical Oncology, 2007
- An In vivo Platform for Translational Drug Development in Pancreatic CancerClinical Cancer Research, 2006
- The Kinase Activity of Fibroblast Growth Factor Receptor 3 with Activation Loop Mutations Affects Receptor Trafficking and SignalingOnline Journal of Public Health Informatics, 2004